Compare ROIV & XP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROIV | XP |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United Kingdom | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 9.9B |
| IPO Year | 2021 | 2019 |
| Metric | ROIV | XP |
|---|---|---|
| Price | $29.34 | $17.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $28.94 | $23.17 |
| AVG Volume (30 Days) | ★ 4.4M | 3.9M |
| Earning Date | 05-28-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 0.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | $19.00 |
| Revenue Next Year | $744.61 | $13.64 |
| P/E Ratio | ★ N/A | $11.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.58 | $15.61 |
| 52 Week High | $30.33 | $23.13 |
| Indicator | ROIV | XP |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 36.82 |
| Support Level | $27.00 | $17.26 |
| Resistance Level | $30.26 | $17.65 |
| Average True Range (ATR) | 0.87 | 0.59 |
| MACD | 0.09 | -0.17 |
| Stochastic Oscillator | 85.95 | 1.02 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission. Geographically, the company derives maximum revenue from Brazil and also has its presence in other countries.